HIV vaccine: It may take two to tango, but no party time yet

Retrovirology

Volumn 6, Issue , 2009, Pages 88-

  Berkhout, Ben ^a   Paxton, William A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALVAC; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; ETHNIC DIFFERENCE; GENETIC ENGINEERING; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PUBLIC HEALTH; RNA VIRUS INFECTION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS VACCINES; BIOMEDICAL RESEARCH; HIV INFECTIONS; HUMANS; THAILAND; UNITED STATES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70449686758     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-6-88     Document Type: Editorial

References (12)

1. Iaccino E, Schiavone M, Fiume G, Quinto I, Scala G. The aftermath of the Merck's HIV vaccine trial. Retrovirology 2008, 5:56. 10.1186/1742-4690-5-56, 2483718, 18597681.
2. Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, Karnasuta C, Polonis VR, Baglyos L, Habib RE, Gurunathan S, Barnett S, Brown AE, Birx DL, McNeil JG, Kim JH. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007, 46:48-55. 10.1097/QAI.0b013e3181576795, 17909315.
3. Ready T. AIDSVAX flop leaves vaccine field unscathed. Nat Med 2003, 9:376. 10.1038/nm0403-376a, 12669041.
4. Desrosiers RC. Prospects for live attenuated HIV. Nature Medicine 1998, 4:982. 10.1038/1949, 9734368.
5. Berkhout B, Verhoef K, van Wamel JLB, Back B. Genetic instability of live-attenuated HIV-1 vaccine strains. J Virol 1999, 73:1138-1145. 103934, 9882315.
6. Perez-Losada M, Posada D, Arenas M, Jobes DV, Sinangil F, Berman PW, Crandall KA. Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial. Retrovirology 2009, 6:67. 10.1186/1742-4690-6-67, 2717047, 19604405.
7. Bontjer I, Land A, Eggink D, Verkade E, Tuin K, Baldwin C, Pollakis G, Paxton WA, Braakman I, Berkhout B, Sanders RW. Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol 2009, 83:368-383. 10.1128/JVI.01404-08, 2612307, 18922866.
8. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004, 5:233-236. 10.1038/ni0304-233, 14985706.
9. Sanders RW, Schiffner L, Master A, Kajumo F, Guo Y, Dragic T, Moore JP, Binley JM. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J Virol 2000, 74:5091-5100. 10.1128/JVI.74.11.5091-5100.2000, 110861, 10799583.
10. Campbell GR, Loret EP. What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?. Retrovirology 2009, 6:50. 10.1186/1742-4690-6-50, 2693501, 19467159.
11. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Reed CK. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009, 15:901-906. 10.1038/nm.1967, 19448633.
12. Verhoef K, Marzio G, Hillen W, Bujard H, Berkhout B. Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat. J Virol 2001, 75:979-987. 10.1128/JVI.75.2.979-987.2001, 113994, 11134311.